ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
07/28/201517:00:35Gilead Sales Soar on Hepatitis Drugs
07/28/201516:34:36Current Report Filing (8-k)
07/28/201516:15:00Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board...
07/28/201512:26:16Merck Earnings Hurt by Arthritis Drug Knockoffs
07/28/201508:23:48Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
07/28/201508:20:10Merck Earnings Top Views Amid Cost Cuts
07/28/201508:12:33Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker
07/28/201507:07:41Current Report Filing (8-k)
07/28/201507:00:00Merck Announces Second-Quarter 2015 Financial Results
07/28/201506:45:00Merck Enhances Immuno-Oncology Portfolio with Acquisition of...
07/28/201506:30:00Merck Announces U.S. Food & Drug Administration Acceptance of...
07/27/201508:30:00Merck Receives Positive CHMP Opinion for Investigational Antibiotic...
07/24/201516:14:52Current Report Filing (8-k)
07/23/201521:27:00MSD annonce que l’Agence européenne du médicament a accepté la d...
07/23/201519:10:00MSD annuncia l'accettazione da parte dell'Agenzia Europea dei...
07/23/201519:06:00MSD meldet Annahme des Zulassungsantrags für Grazoprevir/Elbasvir...
07/23/201513:35:12Bristol-Myers Revenue Boosted by Cancer Drug Opdivo
07/23/201511:02:00MSD Announces European Medicines Agency Acceptance of Marketing...
07/23/201511:02:00Merck Announces European Medicines Agency Acceptance of Marketing...
07/22/201513:28:00Merck Announces Fourth-Quarter 2015 Dividend

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad